Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin alone or with Gemcitabine vs Docetaxel in NSCLC
NCT01951157Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Sep 2013
- Primary completion
- Nov 2016
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lurbinectedin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by PharmaMar. Primary endpoint: Progression-free Survival Rate at Four Months at 4 months. Started Sep 2013; status: completed.
02
Drugs
lurbinectedin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01951157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951157.